Steve K. Cho

Steve K. Cho

Auto-generated profile, based on publicly available information

Steve K. Cho

Department of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Cell Metabolism
Verified
Journal Article
Closed access
IMIsaac Marin-Valencia
Isaac Marin-Valencia
CYChendong Yang
Chendong Yang
TMTomoyuki Mashimo
Tomoyuki Mashimo
SCSteve Cho
Steve Cho
HBHyeonman Baek
Hyeonman Baek
RBRobert M. Bachoo
Robert M. Bachoo

1 January 2010 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CMCalin O. Marian
Calin O. Marian
SCSteve K. Cho
Steve K. Cho
BMBrian M. Mcellin
Brian M. Mcellin
EMElizabeth A. Maher
Elizabeth A. Maher
KHKimmo J. Hatanpaa
Kimmo J. Hatanpaa
RBRobert M. Bachoo
Robert M. Bachoo
Purpose: Telomerase activity is one of the hallmarks of cancer and is a highly relevant therapeutic target. The effects of a novel human telomerase antagonist, imetelstat, on primary human glioblastoma (GBM) tumor-initiating cells were investigated in vitro and in vivo. Experimental Design: Tumor-initiating cells were isolated from primary GBM tumors and expanded as neurospheres in vitro. The GBM tumor-initiating cells were treated with imetelstat and examined for the effects on telomerase activity levels, telomere length, proliferation, clonogenicity, and differentiation. Subsequently, mouse orthotopic and subcutaneous xenografts were used to assess the in vivo efficacy of imetelstat. Results: Imetelstat treatment produced a dose-dependent inhibition of telomerase (IC50 0.45 μmol/L). Long-term imetelstat treatment led to progressive telomere shortening, reduced rates of proliferation, and eventually cell death in GBM tumor-initiating cells. Imetelstat in combination with radiation and temozolomide had a dramatic effect on cell survival and activated the DNA damage response pathway. Imetelstat is able to cross the blood-brain barrier in orthotopic GBM xenograft tumors. Fluorescently labeled GBM tumor cells isolated from orthotopic tumors, following systemic administration of imetelstat (30 mg/kg every day for three days), showed ∼70% inhibition of telomerase activity. Chronic systemic treatment produced a marked decrease in the rate of xenograft subcutaneous tumor growth. Conclusion: This preclinical study supports the feasibility of testing imetelstat in the treatment of GBM patients, alone or in combination with standard therapies. Clin Cancer Res; 16(1); 154–63

14 November 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
YWYuan Wan
Yuan Wan
YKYoung Tae Kim
Young Tae Kim
NLNa Li
Na Li
SCSteve K. Cho
Steve K. Cho
RBRobert Bachoo
Robert Bachoo
SISamir Iqbal
Samir Iqbal
Exposing rare but highly malignant tumor cells that migrate from the primary tumor mass into adjacent tissue(s) or circulate in the bloodstream is critical for early detection and effective intervention(s). Here, we report on an aptamer-based strategy directed against epidermal growth factor receptor (EGFR), the most common oncogene in glioblastoma (GBM), to detect these deadly tumor cells. GBMs are characterized by diffuse infiltration into normal brain regions, and the inability to detect GBM cells renders the disease surgically incurable with a median survival of just 14.2 months. To test the sensitivity and specificity of our platform, anti-EGFR RNA aptamers were immobilized on chemically modified glass surfaces. Cells tested included primary human GBM cells expressing high levels of the wild-type EGFR, as well as genetically engineered murine glioma cells overexpressing the most common EGFR mutant (EGFRvIII lacking exons 2–7) in Ink4a/Arf-deficient astrocytes. We found that surfaces functionalized with anti-EGFR aptamers could capture both the human and murine GBM cells with high sensitivity and specificity. Our findings show how novel aptamer substrates could be used to determine whether surgical resection margins are free of tumor cells, or more widely for detecting tumor cells circulating in peripheral blood to improve early detection and/or monitoring residual disease after treatment. Cancer Res; 70(22); 9371–80. ©2010 AACR.

1 January 2017 in Cell Reports
Verified
Journal Article
Open access
DSDinesh K. Singh
Dinesh K. Singh
RKRahul K. Kollipara
Rahul K. Kollipara
VVVamsidara Vemireddy
Vamsidara Vemireddy
XYXiao-Li Yang
Xiao-Li Yang
YSYuxiao Sun
Yuxiao Sun
RBRobert M. Bachoo
Robert M. Bachoo
Efforts to identify and target glioblastoma (GBM) drivers have primarily focused on receptor tyrosine kinases (RTKs). Clinical benefits, however, have been elusive. Here, we identify an SRY-related box 2 (SOX2) transcriptional regulatory network that is independent of upstream RTKs and capable of driving glioma-initiating cells. We identified oligodendrocyte lineage transcription factor 2 (OLIG2) and zinc-finger E-box binding homeobox 1 (ZEB1), which are frequently co-expressed irrespective of driver mutations, as potential SOX2 targets. In murine glioma models, we show that different combinations of tumor suppressor and oncogene mutations can activate Sox2, Olig2, and Zeb1 expression. We demonstrate that ectopic co-expression of the three transcription factors can transform tumor-suppressor-deficient astrocytes into glioma-initiating cells in the absence of an upstream RTK oncogene. Finally, we demonstrate that the transcriptional inhibitor mithramycin downregulates SOX2 and its target genes, resulting in markedly reduced proliferation of GBM cells in vivo.

Verified
Journal Article
Open access
PDF file
CLCho-Rong Lee
Cho-Rong Lee
WLWongeun Lee
Wongeun Lee
SCSteve K. Cho
Steve K. Cho
Sung-Gyoo ParkSung-Gyoo Park
Sung-Gyoo Park
Myeloid-derived suppressor cells (MDSCs) regulate T cell immunity, and this population is a new therapeutic target for immune regulation. A previous study showed that transforming growth factor-β (TGF-β) is involved in controlling MDSC differentiation and immunoregulatory function in vivo. However, the direct effect of TGF-β on MDSCs with various cytokines has not previously been tested. Thus, we examined the effect of various cytokine combinations with TGF-β on MDSCs derived from bone marrow cells. The data show that different cytokine combinations affect the differentiation and immunosuppressive functions of MDSCs in different ways. In the presence of TGF-β, interleukin-6 (IL-6) was the most potent enhancer of MDSC function, whereas granulocyte colony-stimulating factors (G-CSF) was the most potent in the absence of TGF-β. In addition, IL-4 maintained MDSCs in an immature state with an increased expression of arginase 1 (Arg1). However, regardless of the cytokine combinations, TGF-β increased expansion of the monocytic MDSC (Mo-MDSC) population, expression of immunosuppressive molecules by MDSCs, and the ability of MDSCs to suppress CD4+ T cell proliferation. Thus, although different cytokine combinations affected the MDSCs in different ways, TGF-β directly affects monocytic-MDSCs (Mo-MDSCs) expansion and MDSCs functions.

1 March 2012 in NMR in Biomedicine
Verified
Journal Article
Closed access
PDF file
IMIsaac Marin‐Valencia
Isaac Marin‐Valencia
SCSteve K. Cho
Steve K. Cho
DRDinesh Rakheja
Dinesh Rakheja
KHKimmo J. Hatanpaa
Kimmo J. Hatanpaa
PKPayal Kapur
Payal Kapur
RBRobert M. Bachoo
Robert M. Bachoo